/

NRSN

NeuroSense Therapeutics Ltd.Closed

3.49+0.01 +0.29%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 4.00 +14.61%

Open

3.77

Prev close

3.48

Day range

3.373.78

52-week range

3.2826.64

Volume

39.89K1.82×

Mkt cap

6.62M

P/E ttm

—

Fwd P/E

-0.75

EPS ttm

-47.10

Div yield

0.00%

Earnings

—

From 52w high

−86.90%

Price Chart

Yahoo Finance · delayed

NRSNOct 13, 2026O 3.77H 3.78L 3.37C 3.49+0.01 (+0.29%)Vol 42.90K

SMA 503.16
SMA 2001.44

1Y change +186.07% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

NRSN NeuroSense Therapeutics Ltd. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −14.25%
1 month: +905.76%
3 months: +378.08%
6 months: +391.55%
Year to date: +353.84%
1 year: +186.07%

Valuation & ownership

Market cap: 6.62M
Enterprise value: 6.17M
P/E (ttm): —
Forward P/E: -0.75
PEG ratio: —
Price / book: —
Price / sales (ttm): —
EV / EBITDA: -0.56
EPS (ttm): -47.10
EPS (forward): -4.68
Beta (5y monthly): 1.64
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 1.90M
Float: 1.19M
Short % of float: 1.80%
Short ratio (days): 0.88
Held by insiders: 31.42%
Held by institutions: 1.05%
Avg volume (3m): 21.87K
50-day average: 7.27
200-day average: 13.93
52-week change: +186.07%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 46.2
vs 50-day SMA: +10.53%
vs 200-day SMA: +142.59%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 21.86%
Realised vol (20d, ann.): 129.3%
From 52-week high: −69.81%
From 52-week low: +1,296.00%

ANR

Analyst Consensus

3 analysts

Consensus

Buy

1.67 on a 1 (strong buy) – 5 (sell) scale

Mean target

78.50

+2,149.28% implied

Low 3.50Median 52.00High 180.00

Recommendation trend

Now2 / 1 / 0
1m ago3 / 0 / 0

DES

About NeuroSense Therapeutics Ltd.

Yahoo Finance profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Sector: Healthcare
Industry: Biotechnology
Employees: 17
Headquarters: Herzliya, Israel
Website: neurosense-tx.com
Officers: Mr. Alon Ben-Noon Co-Founder, CEO & Director
Mr. Or Eisenberg Chief Financial Officer
Dr. Niva Russek-Blum Ph.D. Chief Technology Officer

SEAS

Seasonality · NRSN

2021–2026 · monthly returns

Strongest month Nov +42.99%Weakest month Jul −23.58%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	19.6	-1.2	-16.9	8.7	0.0	-12.3	-35.4	-8.2	-48.1	-21.2			−77.3%
2025	-7.5	-0.2	-16.1	5.4	57.1	22.7	-4.8	-41.1	17.9	-10.4	6.2	-35.4	−35.9%
2024	59.2	41.6	2.8	-25.8	-20.0	3.7	-32.1	17.1	42.7	-1.6	-21.6	22.4	+52.9%
2023	27.0	20.0	-7.5	17.4	-22.8	-4.5	-12.8	-27.7	-24.5	-35.1	179.8	-39.1	−35.7%
2022	-19.9	32.0	52.7	-57.7	-16.1	139.7	-44.7	4.3	-8.2	-10.6	7.5	-29.1	−50.4%
2021													—

INSD

Insider Activity · NRSN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 15, 2026	Eisenberg OrChief Financial Officer	Purchase at price 0.80 per share.	250K	$200.00K
Jun 15, 2026	Ben-Noon AlonChief Executive Officer	Purchase at price 0.80 per share.	250K	$200.00K
Mar 25, 2026	Eisenberg OrChief Financial Officer	—	200K	—
Mar 25, 2026	Binder HagitOfficer	—	200K	—
Mar 25, 2026	Russek-Blum NivaChief Technology Officer	—	200K	—

NRSN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

NRSN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About NeuroSense Therapeutics Ltd.

Seasonality · NRSN

Insider Activity · NRSN

Congress Trades · NRSN

Investors Holding NRSN

Investors Holding NRSN

Congress Trades · NRSN

Insider Activity · NRSN

Seasonality · NRSN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About NeuroSense Therapeutics Ltd.

Financial Snapshot

Earnings & Dividends

News